



Exeltis UK Ltd – Methodology Note on Transfer of Value (ToV) to Health Professionals, Other Relevant Decision Makers, Healthcare Organisations, and Members of the Public in the UK in 2024

In accordance with the requirements of the Association of the British Pharmaceutical Industry (ABPI) 2024 Code of Practice for the Pharmaceutical Industry, where applicable, Exeltis UK Ltd (Exeltis) has publicly disclosed certain transfers of value made directly or indirectly to health professionals (HCP), other relevant decision makers (ORDMs), healthcare organisations (HCOs), patient organisations, and members of the public in the UK.

This note summarises the methodologies used by Exeltis in preparing these ToV disclosures. Exeltis ToVs include:

- Donations and grants provided to healthcare organisations, institutions and other organisations
- Fees and expenses paid for contracted services between Exeltis and institutions, organisations, or associations of health professionals
- Support of attendance by health professionals and ORDMs at events/meetings whether paid directly, indirectly or via another party. Fees and expenses paid to health professionals and ORDMs, or to their employers on their behalf.
- Sponsorship, including contributions to costs related to meetings/events paid to healthcare organisations or to organisations managing events on their behalf, which may include support of health professionals not known to the company via the healthcare organisation by way of registration fees, accommodation and travel.

For the purposes of this disclosure, Exeltis has collectively defined donations and grants as providing funds, benefits-in-kind or services freely given for the purposes of supporting healthcare, scientific research, or education, with no consequent obligation on the recipient organisation, institution and the like to provide goods or services to the benefit of Exeltis in return. In general, donations are physical items, services or benefits-in-kind which may be offered or requested. Grants are the provision of funds.

Sponsorship is defined as a contribution, financial or otherwise, in whole or in part provided by or on behalf of Exeltis, towards an activity (including an event/meeting or material) performed, organised, created etc by a healthcare organisation, patient organisation or other independent organisation.

Consent from the HCPs and ORDMs to disclose these transfers of value have been obtained on an individual activity basis through signed consultancy agreements or other written communication. Where HCP and ORDM recipients of ToV cannot be identified for legal reasons, the amount attributable to such transfers have been disclosed on an aggregate basis. The number of recipients involved have been stated together with the percentage of all recipients that they represent and the aggregate amount attributable to ToVs to such HCP and ORDM recipients.

Disclosed payments relate to ToVs where the payment transaction was completed in 2024. Any transfers of value relating to activity that spans two calendar years are disclosed in the year the transfer was completed.

All transfers of value are disclosed in British Pounds Sterling. VAT has been excluded in the disclosed payments.

No non-monetary TOVs were made by Exeltis in 2024.

No ToVs relating to R&D, collaborative working with other pharmaceutical companies or healthcare organisations were made by Exeltis in 2024.

No transfers of value relating to contracted services provide by patient organisations or members of the public were made by Exeltis in 2024.

Contact details for ToV related enquiries: uk.office@exeltis.com

Date of preparation March 2025